HEALTH● LOWAug 6 · Aug 6, 2026, 5:35 PM
Lexicon anticipates Zynquista NDA resubmission in Q4 2026 as SONATA-HCM top line data expected in Q1 2027
Seeking Alpha Tech
Lexicon expects to resubmit the New Drug Application (NDA) for Zynquista in the fourth quarter of 2026. Additionally, top-line data from the SONATA-HCM trial is anticipated in the first quarter of 2027.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH47m ago‘There are trade-offs’: how Hong Kong patients can use telemedicine wiselySouth China Morning PostHEALTH1h agoGermany, Kosovo unite against ticks carrying deadly virusDW News [en]HEALTH2h agoResentment, an emotional wound from the past that harms the bodyClarínHEALTH2h agoAníbal Lotocki's horror operating room: audios, witnesses, and new expert reports further complicate the surgeon's situationClarín